Since the beginning of the recent Ebola virus disease (EVD) outbreak in March 2014, a great sense of fear has developed around the epidemic in highly affected nations, such as Sierra Leone, Liberia, and Guinea, as well as among nations with high potential for importing infection, including the United States.
1
In West Africa, this fear is largely due to Ebola spread in areas with faulty health care systems, which are ill equipped to contain the outbreak. Most hospitals in all countries lack training on proper use of comprehensive personal protective equipment and effective quarantine wards for containing Ebola, leading to greater spread of the virus through the local population and health care professionals.
2
Cases have occurred where foreign aid workers have brought the Ebola virus back to their home countries.Reference Vogel
3
This lapse in the execution of proper safety protocol may have led to hospitals being the main vehicle for the spread of the Ebola epidemic, according to Khan et alReference Khan, Tshioko and Heymann
4
and Jones.Reference Jones
5
This outbreak of EVD has manifested itself in both urban and rural areas, increasing the possible number of people exposed and causing 5000 deaths by October 2014.
1
,
Reference Jones
5
Many families continue traditional burial rituals for relatives who died of EVD. These rituals, which involve touching and kissing the dead, can lead to the spread of Ebola infection.Reference Khan, Tshioko and Heymann
4
If victims of EVD survive infection, they have an amazing advantage. Ebola survivors are resistant to future infections and can help care for patients newly infected with EVD. A large part of stopping this outbreak is communicating with indigenous peoples about proper care, which involves the use of sterile technique when working with patients and maintaining homeostasis.Reference Williams
6
This is not without its challenges because a stigma against Ebola survivors can exist.Reference Hewlett and Amola
7
The current epidemic has reached the United States. This is likely due to a long incubation periodReference Casillas, Nyamathi and Sosa
8
as well as the increased frequency of travel. Despite this scary notion of the virus’s spread to the West, the likelihood of coming into contact with someone infected with Ebola in the United States is currently low. Media sensationalism and improper knowledge of the current Ebola outbreak may have contributed to the hysteria we are currently experiencing. When information has been exaggerated or incorrectly stated, it can actually hinder efforts to combat an outbreak, which is the opposite of the intended effect.Reference Lowery, Evans and Gower
9
The media could mitigate this effect by informing the public of reliable resources, such the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO).
With the arrival of Ebola to the United States, efforts to combat it have massively increased. The Obama administration deployed 4000 specialized military personnel to Ebola-affected countries in West Africa and pledged to donate $500 million to combat the outbreak.Reference Linshi
10
In addition, many private organizations and individuals, such as the Bill and Melinda Gates Foundation and Paul Allen, have pledged to donate $50 million and $100 million, respectively.Reference Folayan
11
,
Reference Molina
12
In addition to donating funds, other avenues of potential aid have tended toward innovation, including the development of rapid detection methods, experimental treatments, and a viable vaccine for the Ebola virus.
During this epidemic, patients have been given an experimental treatment, ZMapp. Although this treatment has demonstrated success in nonhuman primates infected with a lethal dose of the Ebola virus,Reference Geisbert
13
this is not a guarantee that it will work in humans. Some Ebola-infected patients have recovered from the disease under this treatment, while others have died. As testing new drugs on humans during outbreaks is usually not permitted, and rightfully so, clinical trials are typically done on patients who have run out of treatment options during a randomized controlled study. Participants in a WHO panel discussion on the ethical implications of using interventions with unknown efficacy and adverse effects for treatment and prevention of Ebola agreed that it would be ethically reasonable if criteria such as transparency and informed consent were followed.
14
With the thousands of deaths occurring, we are in dire need of a new tool to use against Ebola. Use of convalescent whole blood or plasma from Ebola survivors is one suggested tool for treatment, though there are potential limitations.Reference Lyon, Mehta and Varkey
15
,
Reference Folayan, Brown and Yakubu
16
Two promising vaccines are currently undergoing phase I clinical trials. One is a chimpanzee adenovirus vaccine involving an Ebola surface protein (ChAd3) made by the US National Institute of Allergy and Infectious Diseases in cooperation with GlaxoSmithKline. The other is a recombinant vesicular stomatitis virus vaccine (VSV-EBOV) developed by the Canadian Public Health Agency and authorized to NewLink Genetics. On October 24, The WHO announced a goal of making millions of doses of these 2 vaccines available by the end of 2015.Reference Morello
17
Many people continue to travel from countries where Ebola is endemic, and some of them may be infectious upon their arrival. But will the vaccines come too late to be used in the current epidemic?
Of equal importance to viable vaccines are rapid diagnostic methods. We need ways to easily and effectively screen large populations for EVD. The current screening method for Ebola is polymerase chain reaction (PCR) based, which can take as long as 5 hours to complete.
18
The necessary equipment is bulky, uses electricity, and requires trained professionals. More desirable are fast-acting, affordable, and portable detection methods. A group in Australia is developing ways to make the PCR detection portable.Reference Inglis
19
An accurate screening tool with these features could be quickly distributed to affected areas, aiding in quarantine efforts and dramatically reducing the time taken to test for Ebola-positive persons compared with current methods. Corgenix has innovative tests currently in stage 1 clinical trials in West Africa, and a screening system dubbed REDS (rapid Ebola detection strips) is currently in preliminary development by 2 students and a postdoctoral fellow at Emory University.Reference Vogel
3
,
Reference Williams
6
Both claim to work as simply as over-the-counter pregnancy tests, although the specifics of sensitivity, specificity, and acceptability of the tests have not been released.
The development of innovative screening methods and vaccine are promising, but it is unlikely that either will be ready in the coming months. This begs the question of what other tools, methods, and technology can be used to effectively stem the spread of the outbreak. Quarantine, increased exit screening for travelers, intense surveillance through government and international health organizations, use of Ebola survivors as a workforce, and rapid building of hospitals are all temporary solutions to this outbreak but are not necessarily innovative. Mass media and mobile communication on Ebola prevention, signs, and symptoms might be one solution to stem the epidemic. This strategy has already shown promise through comprehensive education programs provided by the WHO and CDC.Reference Frieden TR and Bell
20
However, traditional aid strategies can only go so far in the absence of scientific discovery. Once more effective treatment and rapid diagnostic tools are available, patients can be identified and treated rapidly. Although we hope the continued outpouring of aid and health care workers to West Africa will reduce the impact of EVD, we can enhance these efforts with Ebola treatments, new testing methods, and vaccine to stop this outbreak.
Since the beginning of the recent Ebola virus disease (EVD) outbreak in March 2014, a great sense of fear has developed around the epidemic in highly affected nations, such as Sierra Leone, Liberia, and Guinea, as well as among nations with high potential for importing infection, including the United States. 1 In West Africa, this fear is largely due to Ebola spread in areas with faulty health care systems, which are ill equipped to contain the outbreak. Most hospitals in all countries lack training on proper use of comprehensive personal protective equipment and effective quarantine wards for containing Ebola, leading to greater spread of the virus through the local population and health care professionals. 2 Cases have occurred where foreign aid workers have brought the Ebola virus back to their home countries.Reference Vogel 3 This lapse in the execution of proper safety protocol may have led to hospitals being the main vehicle for the spread of the Ebola epidemic, according to Khan et alReference Khan, Tshioko and Heymann 4 and Jones.Reference Jones 5
This outbreak of EVD has manifested itself in both urban and rural areas, increasing the possible number of people exposed and causing 5000 deaths by October 2014. 1 , Reference Jones 5 Many families continue traditional burial rituals for relatives who died of EVD. These rituals, which involve touching and kissing the dead, can lead to the spread of Ebola infection.Reference Khan, Tshioko and Heymann 4 If victims of EVD survive infection, they have an amazing advantage. Ebola survivors are resistant to future infections and can help care for patients newly infected with EVD. A large part of stopping this outbreak is communicating with indigenous peoples about proper care, which involves the use of sterile technique when working with patients and maintaining homeostasis.Reference Williams 6 This is not without its challenges because a stigma against Ebola survivors can exist.Reference Hewlett and Amola 7
The current epidemic has reached the United States. This is likely due to a long incubation periodReference Casillas, Nyamathi and Sosa 8 as well as the increased frequency of travel. Despite this scary notion of the virus’s spread to the West, the likelihood of coming into contact with someone infected with Ebola in the United States is currently low. Media sensationalism and improper knowledge of the current Ebola outbreak may have contributed to the hysteria we are currently experiencing. When information has been exaggerated or incorrectly stated, it can actually hinder efforts to combat an outbreak, which is the opposite of the intended effect.Reference Lowery, Evans and Gower 9 The media could mitigate this effect by informing the public of reliable resources, such the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO).
With the arrival of Ebola to the United States, efforts to combat it have massively increased. The Obama administration deployed 4000 specialized military personnel to Ebola-affected countries in West Africa and pledged to donate $500 million to combat the outbreak.Reference Linshi 10 In addition, many private organizations and individuals, such as the Bill and Melinda Gates Foundation and Paul Allen, have pledged to donate $50 million and $100 million, respectively.Reference Folayan 11 , Reference Molina 12 In addition to donating funds, other avenues of potential aid have tended toward innovation, including the development of rapid detection methods, experimental treatments, and a viable vaccine for the Ebola virus.
During this epidemic, patients have been given an experimental treatment, ZMapp. Although this treatment has demonstrated success in nonhuman primates infected with a lethal dose of the Ebola virus,Reference Geisbert 13 this is not a guarantee that it will work in humans. Some Ebola-infected patients have recovered from the disease under this treatment, while others have died. As testing new drugs on humans during outbreaks is usually not permitted, and rightfully so, clinical trials are typically done on patients who have run out of treatment options during a randomized controlled study. Participants in a WHO panel discussion on the ethical implications of using interventions with unknown efficacy and adverse effects for treatment and prevention of Ebola agreed that it would be ethically reasonable if criteria such as transparency and informed consent were followed. 14 With the thousands of deaths occurring, we are in dire need of a new tool to use against Ebola. Use of convalescent whole blood or plasma from Ebola survivors is one suggested tool for treatment, though there are potential limitations.Reference Lyon, Mehta and Varkey 15 , Reference Folayan, Brown and Yakubu 16
Two promising vaccines are currently undergoing phase I clinical trials. One is a chimpanzee adenovirus vaccine involving an Ebola surface protein (ChAd3) made by the US National Institute of Allergy and Infectious Diseases in cooperation with GlaxoSmithKline. The other is a recombinant vesicular stomatitis virus vaccine (VSV-EBOV) developed by the Canadian Public Health Agency and authorized to NewLink Genetics. On October 24, The WHO announced a goal of making millions of doses of these 2 vaccines available by the end of 2015.Reference Morello 17 Many people continue to travel from countries where Ebola is endemic, and some of them may be infectious upon their arrival. But will the vaccines come too late to be used in the current epidemic?
Of equal importance to viable vaccines are rapid diagnostic methods. We need ways to easily and effectively screen large populations for EVD. The current screening method for Ebola is polymerase chain reaction (PCR) based, which can take as long as 5 hours to complete. 18 The necessary equipment is bulky, uses electricity, and requires trained professionals. More desirable are fast-acting, affordable, and portable detection methods. A group in Australia is developing ways to make the PCR detection portable.Reference Inglis 19 An accurate screening tool with these features could be quickly distributed to affected areas, aiding in quarantine efforts and dramatically reducing the time taken to test for Ebola-positive persons compared with current methods. Corgenix has innovative tests currently in stage 1 clinical trials in West Africa, and a screening system dubbed REDS (rapid Ebola detection strips) is currently in preliminary development by 2 students and a postdoctoral fellow at Emory University.Reference Vogel 3 , Reference Williams 6 Both claim to work as simply as over-the-counter pregnancy tests, although the specifics of sensitivity, specificity, and acceptability of the tests have not been released.
The development of innovative screening methods and vaccine are promising, but it is unlikely that either will be ready in the coming months. This begs the question of what other tools, methods, and technology can be used to effectively stem the spread of the outbreak. Quarantine, increased exit screening for travelers, intense surveillance through government and international health organizations, use of Ebola survivors as a workforce, and rapid building of hospitals are all temporary solutions to this outbreak but are not necessarily innovative. Mass media and mobile communication on Ebola prevention, signs, and symptoms might be one solution to stem the epidemic. This strategy has already shown promise through comprehensive education programs provided by the WHO and CDC.Reference Frieden TR and Bell 20 However, traditional aid strategies can only go so far in the absence of scientific discovery. Once more effective treatment and rapid diagnostic tools are available, patients can be identified and treated rapidly. Although we hope the continued outpouring of aid and health care workers to West Africa will reduce the impact of EVD, we can enhance these efforts with Ebola treatments, new testing methods, and vaccine to stop this outbreak.
Acknowledgment
We would like to acknowledge Mr Rostam Zafari and Dr Justine Liepkalns for their contributions to this article.